← boardnext 2027-12
STRO
Sutro Biopharma, Inc.distress 5/10 · elevated risk$22.69-3%today-45% from 52w high
Oncology 4
Lead: Lung Cancer · target FOLR1 · est. market ~$35B (approx, global)
Revenue
$15M
Liquidity
$203M
Runway
1.3 yrs
Shares 1y
-80%
Price & events
+39.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
-4.4%
1W
-22.3%
1M
-34.9%
3M
+50.8%
6M
+163.8%
1Y
-41.7%
2Y
-86.7%
5Y
-89.1%
All
Overview
- Market Cap
- $375.98M
- Volume
- 10.86K
- 52 Week Range
- $7.30 – $40.91
- Total Shares
- 16.57M
- Float Shares
- 10.30M
- Short %
- 8.24%
- % Held by Insiders
- 2.26%
- % Held by Institutions
- 87.40%
- RVOL
- 0.03x
- Beta
- 1.52
Pipeline stages · 2 programs
STRO-004, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Luveltamab tazevibulin, Pegfilgrastim, GemcitabineFOLR1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2027-12-31 | Phase 1 | STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | — | recruiting |
| 2025-08-26 | Phase 2/3 | Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer | 600 | terminated |
| 2025-06-01 | Phase 1/2 | Luveltamab tazevibulin | Acute Myeloid Leukemia (AML) | 24 | terminated |
| 2025-06-01 | Phase 1 | STRO-002, Bevacizumab | Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 58 | terminated |
| 2025-05-01 | Phase 2 | Luveltamab tazevibulin | Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell | 0 | withdrawn |
Catalyst news & presentations · 1
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)STRO-006 · Expected IND submission for ITGB6-targeting ADCSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $48 (+110% upside) · 12 analysts
- 2026-05-28BarclaysOverweight
- 2026-05-15WedbushNeutral → Outperform
- 2026-05-15Leerink PartnersOutperform
- 2026-05-15HC Wainwright & Co.Buy
- 2026-04-30MizuhoOutperform
- 2026-04-23CitizensMarket Outperform
Competitors — FOLR1
- none identified
Recent news
- 2026-07-08Price to earnings forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
- 2026-07-04Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
- 2026-06-28Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000 Value Benchmark - marketscreener.com
- 2026-06-28Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2500 Index - marketscreener.com
- 2026-06-28Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell Small Cap Completeness Index - marketscreener.com
- 2026-06-28Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Dynamic Index - marketscreener.com
- 2026-06-26STRO Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-09Sutro Biopharma (STRO) Proxy filing Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.